Recent AVIR News
- Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 • GlobeNewswire Inc. • 04/29/2024 11:00:00 AM
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients • GlobeNewswire Inc. • 03/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:18:59 PM
- Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:29:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:26:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:25:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:24:58 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:15:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:15:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:15:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:15:01 PM
- Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 • GlobeNewswire Inc. • 01/08/2024 09:05:00 PM
- Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 • GlobeNewswire Inc. • 11/13/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:43:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:15:42 PM
- Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/08/2023 09:05:00 PM
- Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences • GlobeNewswire Inc. • 11/08/2023 12:00:00 PM
- Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 • GlobeNewswire Inc. • 11/02/2023 11:00:00 AM
- Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023 • GlobeNewswire Inc. • 11/01/2023 11:00:00 AM
- Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference • GlobeNewswire Inc. • 09/06/2023 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:46:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:21:00 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM